A review of disease-modifying therapies for MS: Maximizing adherence and minimizing adverse events

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 77-92

  Brandes, David W ^a   Callender, Teri ^b   Lathi, Ellen ^c   O'Leary, Shirley ^d,e  

^a Northridge MS Center   (United States)

^b Heart Center of Sarasota   (United States)

^c MS Center at St Elizabeth's   (United States)

^d HealthSouth Rehabilitation Hospital   (United States)

^e Multiple Sclerosis Center at Texas Neurology   (United States)

Author keywords

Adherence; Glatiramer acetate; Interferon beta; Multiple sclerosis; Natalizumab

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOXIFYLLINE; SEROTONIN UPTAKE INHIBITOR; THIOPURINE METHYLTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ACUTE LEUKEMIA; ALOPECIA; AMENORRHEA; AMINO ACID SEQUENCE; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; AUTOIMMUNE HEPATITIS; BLADDER FIBROSIS; BLOOD CELL COUNT; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BRAIN TUMOR; CARDIOMYOPATHY; CARDIOTOXICITY; CATARACT; CHEST TIGHTNESS; CHILL; CHOLELITHIASIS; CINAHL; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; COST OF ILLNESS; CREATININE BLOOD LEVEL; CYSTITIS; DATA BASE; DECISION MAKING; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISABILITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG SUBSTITUTION; DYSPNEA; ECHOCARDIOGRAPHY; EMOTIONAL STRESS; ERYTHEMA; FATIGUE; FEMALE INFERTILITY; FETUS DEATH; FETUS DISEASE; FEVER; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; FLUID RETENTION; FLUSHING; GASTROESOPHAGEAL REFLUX; GENETIC SCREENING; GINGIVITIS; GLYCOSYLATION; HASHIMOTO DISEASE; HEADACHE; HEALTH CARE PERSONNEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; HUMAN RELATION; HYPERCOAGULABILITY; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTHYROIDISM; INDIGESTION; INFECTION; INFECTION RISK; INFLAMMATION; INFORMATION RETRIEVAL; INFUSION REACTION; INJECTION PAIN; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INSOMNIA; INTERPERSONAL COMMUNICATION; IRRITABILITY; KIDNEY FUNCTION TEST; LEUKEMIA; LEUKOPENIA; LIPOATROPHY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG DISEASE; LUNG EDEMA; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; MALAISE; MEDLINE; MENSTRUATION DISORDER; MONITORING; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NITROGEN BALANCE; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL EDEMA; PHARYNGITIS; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PUBLICATION; RASH; RAYNAUD PHENOMENON; RELAPSE; REVERSIBLE INTERSTITIAL PNEUMONITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; SHORT COURSE THERAPY; SIDE EFFECT; SINUS CONGESTION; SKIN MANIFESTATION; STEATORRHEA; STERILE HEMORRHAGIC CYSTITIS; STOMATITIS; SUBACUTE THYROIDITIS; T CELL LYMPHOMA; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT REFUSAL; UREA NITROGEN BLOOD LEVEL; UREMIA; URINARY TRACT INFECTION; UROSEPSIS; URTICARIA; VEIN THROMBOSIS; PSYCHOLOGICAL ASPECT;

HUMANS; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE;

EID: 64249093467     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802569455     Document Type: Review

References (151)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146
2. National MS Society. Comparing the disease-modifying drugs. Available at: http://www.nationalmssociety.org/Brochures- Comparing.asp [Last accessed 21 August 2006]
3. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;4:CD001331
4. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
5. Jacobs L, Cookfair D, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294 (Pubitemid 26100751)
6. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504
7. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708 (Pubitemid 28146153)
8. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910 (Pubitemid 43313657)
9. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904 (Pubitemid 30727801)
10. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis. Lancet 2001;357:1576-1582 (Pubitemid 32488815)
11. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249 (Pubitemid 44563835)
12. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025 (Pubitemid 36026580)
13. Fox E. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006;28:461-474 (Pubitemid 44208782)
14. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247 (Pubitemid 32947383)
15. Bergh FT, Kumpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurology 2006;6:19-28
16. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-582 (Pubitemid 41387703)
17. La Mantia L, D'Amico D, Rigamonti A, et al. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler 2006;12:476-480 (Pubitemid 44132588)
18. Goodkin DE, Rudick RA, Medendorp SV, et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40
19. Pulicken M, Bash CN, Costello K, et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination in multiple sclerosis. Mult Scler 2005;11:169-174 (Pubitemid 40403255)
20. British and Dutch Multiple Sclerosis Azathioprine Trial Group Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-183
21. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study. The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology 2003;60:1849-1851
22. Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis. Arch Neurol 2004;61:1409-1412
23. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281 (Pubitemid 28240339)
24. Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European study on intravenous immunoglobulin in secondary progressive multiple sclerosis (ESIMS). Mult Scler 2005; 11:433-440 (Pubitemid 40984238)
25. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-1156 (Pubitemid 39296602)
26. Vollmer TL, Hadjimicahel O, Preiningerova J, et al. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and non-veterans. J Rehabil Res Dev 2002;39:163-174 (Pubitemid 34627416)
27. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 2005; 11:33-40 (Pubitemid 40259972)
28. Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005;45:371-375 (Pubitemid 46037299)
29. Fraser C, Morgante L, Hadjimichael O, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120-129
30. Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey. Neurology 1999; 52:A549
31. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003; 61:551-554
32. Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-132 (Pubitemid 32488430)
33. Low A, Markowitz M. Predictors of response to highly active antiretroviral therapy. AIDS Read 2006;168:425-8, 430 (Pubitemid 44651646)
34. World Health Organization. Adherence to long-term therapies. Evidence for action. 2003. Available at: http://www.who.int/ chronic-conditions/en/ adherence-report.pdf [Last accessed 21 August 2006]
35. Treadaway K, Brannon K, Morrison A, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis [P01.071]. Presented at: 58th Annual Meeting of the American Academy of Neurology, April 1-8, 2006; San Diego, CA
36. Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehab Nurs 2001;26:172-176
37. Becker MH. The health belief model and personal health behavior. Health Educ Monogr 1974;2:324-508
38. Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehab Nurs 2001;26:221-226
39. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. In: Hersen M, Eisler RM, Miller PM, eds. Progress in Behavior Modification. Sycamore, IL: Sycamore Publishing Co., 1992
40. Runmarker B, Anderson O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134 (Pubitemid 23087038)
41. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999;5:369-370 (Pubitemid 29505053)
42. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-177 (Pubitemid 43970148)
43. DeSousa EA, Albert RH, Kalman B. Cognitive impairments in multiple sclerosis: a review. Am J Alzheimer's Dis Other Dement 2002;17:23-29 (Pubitemid 34106522)
44. Rao SM. Cognitive function in patients with multiple sclerosis: impairment and treatment. Int J MS Care 2004;1:9-22
45. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al. The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol 1991;30:333-348
46. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta- 1a in relapsing MS. Neurology 2001;56:1628-1636
47. Johnson JP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45:1268-1276
48. Comi G, Filippi M, Wolinsky J; the European/Canadian Copaxone Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing- remitting multiple sclerosis. Ann Neurol 2001;49:290-297
49. Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-893 (Pubitemid 27508924)
50. O'Connell D. Is it an MS attack - or not? National MS Society: Inside MS. 2004. Available at: http://www.nationalmssociety. org/IMSJuly04-MSAttackOrNot. asp [Last accessed 14 September 2006]
51. Runkel L, Meier W, Blake R, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res 1998;15:641-649 (Pubitemid 28214960)
52. Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2006
53. Rebif [package insert]. Rockland, MA: Serono, Inc.; 2005
54. Betaseron [package insert]. Montville, NJ: Berlex Laboratories; 2003
55. Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22:149-159 (Pubitemid 30072059)
56. Frohman EM, Brannon K, Alexander S, et al. Disease-modifying agent-related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 2004;10:302-307 (Pubitemid 38807459)
57. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 2005;2:8-13 (Pubitemid 40179012)
58. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002;359: 1453-1460 (Pubitemid 34457761)
59. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
60. Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients. A randomized, multicenter study. Neurology 2005;64:621-630
61. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584
62. Inafuku H, Khan MAK, Nagata T, Nonaka S, et al. Cutaneous ulcerations following subcutaneous interferon β injection to a patient with multiple sclerosis. J Dermatol 2004;31:671-677 (Pubitemid 39243792)
63. Feldmann R, Low-Weiser H, Duschet P, et al. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatology 1997;195:52-53 (Pubitemid 27326712)
64. Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365-367 (Pubitemid 26059484)
65. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs 2005;19:1-14
66. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-236 (Pubitemid 34810404)
67. Avonex [medication guide]. Cambridge, MA: Biogen Idec, Inc.; 2006
68. Rebif [medication guide]. Rockland, MA: Serono, Inc.; 2005
69. Tornatore C, Bartlett D. Tolerability of interferon beta-1b (Betaferon®/Betaseron®) can be significantly improved using both interferon-free needle and automated injection techniques. J Neurol 2002;249:I/205
70. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. On behalf of the Rebiject Study Group. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11:585-591
71. Rio J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004;63:525-528
72. Rees J, Haas J, Gabriel K, et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15-18 (Pubitemid 34193022)
73. Rice GP, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 1999;52:1893-1895 (Pubitemid 29260906)
74. Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309-318 (Pubitemid 40740466)
75. Brandes D, Bigley GK, Warth J, et al. (S08) Flu-like symptoms in MS patients on IM IFNβ-1a therapy: management strategies. Poster presented at: Navigating the World of Multiple Sclerosis (CMSC); June 1-5, 2005; Orlando, FL
76. Patten SB, Fridhandler S, Beck CA, et al. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9:616-620 (Pubitemid 37479412)
77. Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175-181 (Pubitemid 40403256)
78. Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005;26:255-262 (Pubitemid 41447824)
79. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996;46:628-632 (Pubitemid 26099623)
80. Zephir H, De Seze J, Stojkovic T, et al. Multiple sclerosis and depression: influence of interferon β therapy. Mult Scler 2003; 9:284-288 (Pubitemid 36681895)
81. Feinstein A, O'Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol 2002;249:815-820 (Pubitemid 34754215)
82. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improved adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533 (Pubitemid 27204238)
83. Durelli L, Ferrero B, Oggero A, et al. Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS. Neurology 2001;57:1363-1370 (Pubitemid 32995712)
84. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS. A comparison between the three products. Neurology 2004;62:628-631
85. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18 (Pubitemid 26157582)
86. Rieckmann P, Weber F, Gunther A, et al. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon- β1b treatment in patients with multiple sclerosis. Neurology 1996;47:604 (Pubitemid 26324075)
87. D'Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004;24:980-984 (Pubitemid 39471926)
88. Pollmann W, Erasmus L-P, Feneberg W, et al. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology 2006;66:275-277 (Pubitemid 43970175)
89. Khromov A, Segal M, Nissinofff J, et al. Migraines linked to interferon β treatment of multiple sclerosis. Am J Phys Med Rehabil 2005;84:644-647 (Pubitemid 41026132)
90. Weber F, Polak T, Gunther A, et al. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:27-34 (Pubitemid 28323652)
91. Neve HJ, Bhatti WA, Soulsby C, et al. Reversal of hair loss following vertical gastroplasty when treated with zinc sulfate. Obes Surg 1996;6:63-65 (Pubitemid 26068245)
92. Kreiss Y, Cohen O, Pras E, et al. Subacute thyroiditis in a patient with MS treated with interferon beta-1a. Neurology 1999;53:1606 (Pubitemid 29491968)
93. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169-1190 (Pubitemid 27396486)
94. McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust N Z J Med 2000;30:278-279 (Pubitemid 30304488)
95. Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999;162:74-83 (Pubitemid 29064122)
96. Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type 1 interferon therapy. Clin Exp Med 2004;3:199-210 (Pubitemid 38570001)
97. Petek-Balci B, Yayla V, Ozer F. Multiple sclerosis and Hashimoto thyroiditis. Two cases. Neurologist 2005;11:301-304 (Pubitemid 41324860)
98. Russo R, Tenembaum S, Moreno MJ, et al. Interferon-β1a- induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque. Arthritis Rheum 2000;43:1190 (Pubitemid 30368205)
99. Altintas A, Alici Y, Melikoglu M, et al. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002;8:534-536 (Pubitemid 35396407)
100. Strueby L, Nair B, Kirk A, et al. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta. Scand J Rheumatol 2005;34:485-488 (Pubitemid 43062207)
101. Nousari HC, Kimyai-asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998;352:1825-1826 (Pubitemid 28550075)
102. Dionisiotis J, Zoukos Y, Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon B treatment. J Neurol Neurosurg Psychiatry 2004;75:1079 (Pubitemid 38869639)
103. Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Neurology 1997;49:1747-1748 (Pubitemid 28015158)
104. De Seze J, Canva-Delcambre V, Fajardy I, et al. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 2005;11:691-693
105. Pulicken M, Koteish A, DeBusk K, et al. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006;66:1954-1955 (Pubitemid 44049842)
106. Linden D. Severe Raynaud's phenomenon associated with interferon-B treatment for multiple sclerosis. Lancet 1998; 352:878-879 (Pubitemid 28416726)
107. Cruz RD. [Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report.] Arq Neuropsiquiatr 2000;58:556-559 [article in Portuguese]
108. Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother 2003;37:77-79
109. Batay F, AlMefty O. Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases. Acta Neurochir Wien 2002;144:365-368 (Pubitemid 34507858)
110. Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-β treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg 2006; 108:259-265 (Pubitemid 43319524)
111. Drevelegas A, Xinou E, Karacostas D, et al. Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship? Neuroradiology 2005;47:516-519
112. Case Records of the Massachusetts General Hospital Case 34-2001. N Engl J Med 2001;345:1409-1415
113. Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-248
114. Copaxone [package insert]. Kansas City, MO: Teva Neuroscience, Inc.; 2006
115. Edgar CM, Brunet DG, Fenton P, et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63 (Pubitemid 38325760)
116. Drago F, Brusati C, Mancardi G, et al. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol 1999;135:1277-1278 (Pubitemid 29493299)
117. Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000;247:220-221 (Pubitemid 30189407)
118. Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001;68:287-288 (Pubitemid 33756729)
119. Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 2004;5:357-359 (Pubitemid 39655099)
120. Windhagen A, Maniak S, Marckmann S, et al. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J Neurol Neurosurg Psychiatry 2001;70:415-416 (Pubitemid 32250914)
121. Flechter S, Kott E, Steiner-Birmanns B, et al. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Clin Neuropharm 2002;25:11-15 (Pubitemid 34178242)
122. Flechter S, Vardi J, Pollak L, et al. Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197:51-55 (Pubitemid 34462144)
123. Beiske AG, Myrh K-M. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol 2006;253:377-378
124. Kauffman CL, Sina B, Costello K, et al. Cutaneous reactions to interferon beta-1b (Betaseron) in multiple sclerosis patients, a clinical and pathological study [abstract]. Am J Dermatopathology 1997;19:512
125. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety 2001; 24:979-990 (Pubitemid 33097098)
126. Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2006
127. Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381 (Pubitemid 41132342)
128. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374 (Pubitemid 41132341)
129. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368 (Pubitemid 41132340)
130. United States Food and Drug Administration. Natalizumab (marketed as Tysabri) information. Available at: http:// www.fda.gov/cder/drug/infopage/ natalizumab/default.htm [Last accessed 11 September 2006]
131. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923 (Pubitemid 43313658)
132. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 2001;12:56-61
133. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906 (Pubitemid 27139818)
134. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991;21:1-11
135. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical- immunologic correlations. Neurology 1986;36:238-243 (Pubitemid 16124215)
136. Hillen HFP, Breed WPM, Botman CJ. Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. Neth J Med 1990;37:231-235
137. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913
138. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-445 (Pubitemid 35041466)
139. Bernitsas E, Wei W, Mikol D. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59:206-209 (Pubitemid 43042892)
140. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. DSM-IV-TR. Washington, DC: American Psychiatric Publishing, 2000
141. Cox D, Mohr DC. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety. Am J Drug Delivery 2003; 1:215-221
142. Pohl D, Rostasy K, Hanefeld F. Multiple sclerosis in childhood and adolescence: treatment with subcutaneous interferonbeta- 1a. Poster presented at: 57th Annual Meeting of the American Academy of Neurology; April 9-16, 2005; Miami, FL, USA
143. Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult Scler 2005;11:182-185 (Pubitemid 40403257)
144. Pfohl DC. A multiple sclerosis (MS) center injection training program. Axon 1997;19:29-33
145. National MS Society. Medicare prescription drug coverage. 2006. Available at: http://www.nationalmssociety.org/ medicare-benefit.asp/2/4 [Last accessed 21 August 2006]
146. National MS Society. Disease management consensus statement. 2006. Available at: http://www.nationalmssociety.org/ pdf/sourcebook/consensus- summary.pdf [Last accessed 21 August 2006]
147. La Mantia L, Milanese C, Mascoli N, et al. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2006; 24:CD002819
148. Vittorio CC, Ricci KT. Monitoring for major side effects of systemic drugs in dermatology. Dermatol Nurs 1996;8:247-259
149. Taylor L, Hughes RAC, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol 2004;11:141 (Pubitemid 38230791)
150. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-718 (Pubitemid 28507145)
151. Zaidan R, Moallem MA, Wani BA, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003;10:367-372 (Pubitemid 41754755)